Zacks: Brokerages Expect Guardant Health Inc (NASDAQ:GH) Will Announce Earnings of -$0.34 Per Share

Equities analysts forecast that Guardant Health Inc (NASDAQ:GH) will post ($0.34) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Guardant Health’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.31). The company is expected to issue its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Guardant Health will report full-year earnings of ($1.46) per share for the current year, with EPS estimates ranging from ($1.51) to ($1.36). For the next fiscal year, analysts expect that the business will report earnings of ($1.05) per share, with EPS estimates ranging from ($1.41) to ($0.88). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Guardant Health.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.05. The company had revenue of $36.66 million for the quarter, compared to analyst estimates of $32.12 million.

Several research analysts have recently weighed in on GH shares. Zacks Investment Research lowered shares of Guardant Health from a “hold” rating to a “sell” rating in a report on Monday, March 18th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a report on Wednesday, March 13th. Canaccord Genuity started coverage on shares of Guardant Health in a report on Tuesday, April 16th. They set a “buy” rating and a $90.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $42.00 to $85.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Finally, Cowen increased their price objective on shares of Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Guardant Health presently has an average rating of “Buy” and a consensus price target of $83.50.

In related news, CEO Helmy Eltoukhy sold 90,000 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $65.28, for a total value of $5,875,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ian T. Clark sold 538 shares of the firm’s stock in a transaction that occurred on Thursday, April 25th. The shares were sold at an average price of $65.11, for a total transaction of $35,029.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 975,338 shares of company stock worth $66,706,026.

A number of large investors have recently modified their holdings of the business. Temasek Holdings Private Ltd acquired a new stake in Guardant Health in the fourth quarter valued at approximately $60,633,000. Orbimed Advisors LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $57,681,000. BlackRock Inc. grew its position in Guardant Health by 1.6% in the first quarter. BlackRock Inc. now owns 1,132,826 shares of the company’s stock valued at $86,888,000 after acquiring an additional 18,315 shares in the last quarter. Jennison Associates LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $31,700,000. Finally, Lord Abbett & CO. LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $20,024,000. 69.15% of the stock is owned by institutional investors.

Shares of NASDAQ:GH traded up $0.58 on Wednesday, reaching $87.69. 28,231 shares of the company were exchanged, compared to its average volume of 1,074,809. Guardant Health has a 1-year low of $27.04 and a 1-year high of $106.58. The stock has a market cap of $7.59 billion and a PE ratio of -31.33.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Read More: Outperform Rating

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.